Evercore ISI raised the firm’s price target on Baxter to $58 from $55 and keeps an Outperform rating on the shares, which the analyst is also adding to the firm’s “Tactical Outperform” list ahead of earnings from the MedTech, Life Science Tools and Diagnostics group. Evercore has “a distinct bias towards mega caps and value/GARP as we head into” Q2, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAX:
Questions or Comments about the article? Write to editor@tipranks.com